HTATIP2 promoter methylation has also been reported from other tumor types [5, 6, 7, 8, 9] and found most commonly in GBM and low‐grade glioma, with 70 to over 80% prevalence, according to a pan‐cancer analysis [10]. This evidence concerns the gene HTATIP2 and glioblastoma.